Perspective on biotech
|14th September 2017
Biotech companies operate in highly complex markets with extremely challenging regulatory constraints. As a creative marketing consultancy we are well positioned to cut through this noise and tackle challenges from all angles, offering leading strategic and creative solutions.
Ahead of our upcoming report into strategic challenges and opportunities in the sector, we have been speaking to biotech experts to find out their perspective on the state of the industry.
Here we explore some of their enlightening insights and reveal how the definition of biotech is changing as big pharma turns its research and development to biological therapies.
Find out about:
- The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques
- How to define a biotech company – is the current definition still valid?
- Shaping the future of healthcare – solving four common challenges facing biotech companies today.
Maximising the commercial potential of the pharmaceutical pipeline
|3rd April 2020
Decisions made early in the drug development process can define the limits of what’s possible for products and portfolios. So, why aren’t commercial teams always involved in these early conversations? In this Q&A we deep dive into early stage strategy, including how to break down these siloes and rethink drug development and clinical trial design.
In-progress treatments for COVID-19: an attempt to simplify things
|27th March 2020
Senior Associate Consultant, Manos Mastorakis, takes a look at a number of COVID-19 drugs that are already registered in clinical trials, providing analysis aiming to simplify the current landscape.
Why I became a multiple myeloma patient advocate
|6th March 2020
BLH speaks to MM patient advocate, Peter McCleave, to find out how he has fought to remain positive throughout his treatment journey while simultaneously leading a successful campaign to get more people to sign up to be a blood stem cell donor.